Intestinal Cell News Volume 10.30 | Sep 20 2024

    0
    17







    2024-09-20 | ICN 10.30


    Intestinal Cell News by STEMCELL Technologies
    Vol. 10.30 – 20 September, 2024
    TOP STORY

    Neoadjuvant Nivolumab and Relatlimab in Locally Advanced MMR-Deficient Colon Cancer: A Phase II Trial

    In the NICHE-3 study, a total of 59 patients with locally advanced mismatch repair deficiency colorectal cancer were treated with two four-weekly cycles of nivolumab plus relatlimab before surgery. Results showed that neoadjuvant nivolumab/relatlimab induced high rates of pathologic responses.
    [Nature Medicine]

    Full Article
    STEMCELL has implemented an Environmental Management System that is now ISO 14001-certified.
    PUBLICATIONSListed by the impact factor of the journal

    Fusobacterium nucleatum Facilitates Anti-PD-1 Therapy in Microsatellite Stable Colorectal Cancer

    The authors deciphered the potential function of Fusobacterium nucleatum in modulating anti-PD-1 monoclonal antibody immunotherapy response in microsatellite stable colorectal cancer and its underlying molecular mechanisms.
    [Cancer Cell]

    Full ArticleGraphical Abstract

    Targeting TL1A and DR3: The New Frontier of Anti-Cytokine Therapy in IBD

    TNF-like cytokine 1A (TL1A) and death-domain receptor 3 (DR3) were expressed by cellular subsets with important roles for the initiation and maintenance of intestinal inflammation, serving as potent universal costimulators of effector immune responses, indicating their participation in the pathogenesis of IBD.
    [Gut]

    Abstract

    Alzheimer’s Disease-Related Presenilins Are Key to Intestinal Epithelial Cell Function and Gut Immune Homoeostasis

    Psen1 expression was regulated in experimental gut inflammation and in patients with IBD. On a molecular level, intestinal epithelial cells lacking Psen showed impaired Notch signaling and dysregulated epithelial differentiation.
    [Gut]

    Abstract

    Human Pluripotent Stem Cell-Derived Organoids Repair Damaged Bowel In Vivo

    Researchers developed a rodent injury model where, through luminal delivery, demonstrated that fragmented human intestinal organoids engrafted, proliferated, and persisted throughout the bowel following repair.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Recruitment of USP10 by GCS1 to Deubiquitinate GRP78 Promotes the Progression of Colorectal Cancer via Alleviating Endoplasmic Reticulum Stress

    Scientists investigated the function and molecular mechanism of glucosidase I (GCS1) in regulating endoplasmic reticulum stress (ER) in colorectal cancer (CRC). GCS1 stimulated CRC growth and migration and reduced ER stress-mediated apoptosis via USP10-mediated deubiquitination of GRP78.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    DCLK1 Induces a Pro-Tumorigenic Phenotype to Drive Gastric Cancer Progression

    The authors showed that the kinase activity of doublecortin-like kinase 1 (DCLK1) orchestrated cancer cell–intrinsic and–extrinsic processes that led to pro-invasive and pro-metastatic reprogramming of gastric cancer cells.
    [Science Signaling]

    Full Article

    The RNA Helicase DDX21 Activates YAP to Promote Tumorigenesis and Is Transcriptionally Upregulated by β-Catenin in Colorectal Cancer

    Investigators showed that DDX21 was a direct transcriptional target gene of β-catenin and mediated the protumorigenic function of β-catenin in colorectal cancer (CRC). Loss of DDX21 led to cytoplasmic translocation and suppressed the proliferation and migration of CRC cells.
    [Oncogene]

    Full Article

    Insidious Chromatin Change with a Propensity to Exhaust Intestinal Stem Cells during Aging

    Through analyses of chromatin accessibility and gene expression in intestinal progenitor cells during aging, researchers discovered changes of chromatin accessibility and gene expression that had a propensity to exhaust intestinal stem cells.
    [iScience]

    Full ArticleGraphical Abstract
    Register now for an on-demand course to culture human intestinal organoids and learn about their downstream applications
    REVIEWS

    Ulcerative Colitis: Clinical Biomarkers, Therapeutic Targets, and Emerging Treatments

    Scientists summarize recent advances in identifying novel clinical biomarkers, diagnostics, treatment targets, and emerging therapeutics in ulcerative colitis.
    [Trends in Pharmacological Sciences]

    Abstract

    Challenges in Validation of Combination Treatment Strategies for CRC Using Patient-Derived Organoids

    The authors discuss the use of patient-derived organoids in validation and optimization of multi-drug combinations for personalized treatment strategies in colorectal cancer.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Stimulus-Responsive Drug Delivery Nanoplatforms for Inflammatory Bowel Disease Therapy

    Investigators provide an overview of the pathophysiological mechanisms underlying IBD and summarize recent advancements in microenvironmental stimulus-responsive nanocarriers for IBD therapy.
    [Acta Biomaterialia]

    AbstractGraphical Abstract
    INDUSTRY AND POLICY NEWS

    UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval

    A University of Chicago (UChicago) Medicine patient became the first in the world to receive the drug guselkumab since its approval by the FDA for treating moderate to severe ulcerative colitis.
    [UChicago Medicine]

    Press Release

    Alamos Gold Helps to Create Inaugural Research Chair to Better Detect and Treat Gastrointestinal Cancers

    Alamos Gold, Inc. announced a contribution to The Princess Margaret Cancer Foundation to create the new Alamos Gold Chair in Gastrointestinal Surgical Oncology. The $2 million contribution will support the new Chair in making an impact on gastrointestinal cancer research.
    [Alamos Gold, Inc. (GlobeNewswire, Inc.)]

    Press Release
    FEATURED EVENT

    36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

    October 23-25, 2024
    Barcelona, Spain

    > See All Events

    JOB OPPORTUNITIES

    Assistant Professor – Gastrointestinal Medical Oncology

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Postdoctoral Associate- Cholesterol and Intestinal Stem Cells

    Baylor College of Medicine – Houston, Texas, United States

    Assistant/Associate/Full/Chair Professor – Medicine

    Westlake University – Zhejiang, China

    PhD Student/Post Doc – Molecular Oncology

    University of Würzburg – Würzburg, Germany

    Post Doc – Precision Oncology of Gastrointestinal Cancers

    City of Hope – Monrovia, California, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2